Compare GraniteShares 2x Long COIN Daily ETF (CONL) vs Quest Diagnostics Inc (DGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GraniteShares 2x Long COIN Daily ETF vs Quest Diagnostics Inc — how do they compare? GraniteShares 2x Long COIN Daily ETF trades at $4.13, while Quest Diagnostics Inc trades at $237.45 (market cap $26.21B). The key difference: Quest Diagnostics Inc pays a 1.45% dividend while GraniteShares 2x Long COIN Daily ETF pays none, and Quest Diagnostics Inc is trading nearer its 52-week high, GraniteShares 2x Long COIN Daily ETF nearer its low. Which is the better fit depends on your goals.
| CONL | DGX | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $48.70 | $238.50 |
52-Week Low | $3.93 | $173.49 |
Market Cap | — | $26.21B |
Enterprise Value | — | $31.97B |
Dividend Yield | — | 1.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CONL (GraniteShares 2x Long COIN Daily ETF) trades at $4.065, down 0.61% on the day, with a bearish technical outlook as moving averages and key indicators signal selling pressure. The ETF has experienced significant volatility, losing 67% year-to-date according to 24/7 Wall Street (2026-06-06), reflecting the inherent risks of daily-reset leveraged strategies. Recent news highlights the challenges of timing leveraged ETF investments, with investors missing substantial returns due to poor trading timing.
The outlook remains challenging given the ETF's structure amplifies daily Coinbase volatility. While cryptocurrency trends may offer occasional upside, the daily reset mechanism creates compounding risks that have eroded value significantly. Investors should understand this is a tactical trading instrument, not a long-term investment vehicle, with high risk of capital erosion during volatile periods.
Quest Diagnostics (DGX) trades at $237.24, down 0.16% on the day, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $3.12 and raising its full-year outlook, driven by robust testing demand. Revenue grew to $11.04B in 2025, with net income of $992M, though margins face pressure from lower-margin deals and rising costs.
The outlook is positive due to raised guidance and AI integration enhancing efficiency, but risks include debt levels and margin compression. Analysts maintain a cautious buy stance with a $249.50 price target, indicating modest upside potential from current levels amid competitive and cost challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About GraniteShares 2x Long COIN Daily ETF
CONL is a leveraged ETF that seeks to provide two times (2x) the daily performance of Coinbase Global (COIN) stock. It is designed for investors seeking magnified short-term exposure to the price movements of Coinbase.
Read more on CONL →About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →
